Silexion Therapeutics Corp. announced new preclinical data showcasing SIL204's successful distribution to major pancreatic cancer metastatic sites following systemic administration.
The study confirmed reductions in tumor burden at clinically relevant doses, validating the systemic component of the dual-route administration strategy.
Results support the potential to target both primary tumors and metastatic disease with SIL204.
Successful Distribution
SIL204 distributed to key organs of metastatic pancreatic cancer, showing measurable reductions in tumor burden.
Validation of Dual-Route Strategy
The study validates the efficacy of the dual-route administration strategy by reaching metastatic sites throughout the body.
Clinical Relevance
Results at mid-range human equivalent doses demonstrate SIL204's potential for planned clinical trials.
Statistically Significant Reductions
Notable reductions in tumor burden were observed in key metastatic sites, supporting the drug's efficacy.
- The ability of SIL204 to reach metastatic sites is crucial in addressing pancreatic cancer mortality attributed to metastatic disease.
- Results offer promise for improved treatment strategies targeting both primary tumors and micrometastases.
- The success of SIL204 in reducing tumor burden across major sites indicates potential for broader therapeutic applications.
Silexion's positive preclinical data and validation of its dual-route administration strategy set the stage for Phase 2/3 trials in 2026, positioning the company as a frontrunner in innovative oncology treatments.